proteomic changes upon treatment with semaglutide in individuals with obesity Frontiers A Multidisciplinary Perspective on Semaglutide

Clinical evidence demonstrates GLP-1 response depends on factors like GLP1R gene variants, baseline insulin resistance, and gastrointestinal sensitivity

The FDA also has a black box warning on metformin as it carries a serious safety risk of lactic acidosis

Stay Hydrated: Drinking plenty of water can help alleviate nausea and support your overall health

Tang, Z

Wegovy, which contains semaglutide, is a GLP-1 agonist approved for weight loss and reducing the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight

Systemic side effects are rare at low doses, with transient nausea or mild headache reported infrequently